Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (NCT06252649)
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (5 items).
Location: Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Active, untreated brain metastases.
- Leptomeningeal disease
- Previous treatment with a KRAS p.G12C inhibitor
- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (291 Sites)
Showing the first 25 of 291 sites.
- Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
- Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
- Cancer and Blood Research Center, LLC — Los Alamitos, California
- California Research Institute — Los Angeles, California
- Norwalk Hospital — Norwalk, Connecticut
- Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
- D and H Cancer Research Center — Margate, Florida
- Mid Florida Hematology and Oncology Centers PA — Orange City, Florida
- Boca Raton Clinical Research Medical Center Inc — Plantation, Florida
- Georgia Cancer Specialists — Atlanta, Georgia
- Insight Research Institute — Chicago, Illinois
- Hope and Healing Cancer Services — Hinsdale, Illinois
- Orchard Healthcare Research Inc — Skokie, Illinois
- Pikeville Medical Center — Pikeville, Kentucky
- Henry Ford Health System — Detroit, Michigan
- Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
- Saint Louis Cancer Care West County — Bridgeton, Missouri
- Minniti Center for Medical Oncology and Hematology — Mickleton, New Jersey
- Duke Cancer Center — Durham, North Carolina
- FirstHealth Cancer Center — Pinehurst, North Carolina
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Carolina Blood and Cancer Care — Rock Hill, South Carolina
- Tennessee Oncology PLLC - Chattanooga — Nashville, Tennessee
- Tennessee Oncology, PLLC — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Colorectal Cancer
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
- Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer — Newark, Delaware
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer — Duarte, California
Explore by condition: All Metastatic Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.